TOP TEN perturbations for 39264_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39264_at
Selected probe(set): 204972_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39264_at (204972_at) across 6674 perturbations tested by GENEVESTIGATOR:
T. cruzi study 1 (HMVEC; 24h; top) / mock infected cardiac microvascular endothelial cell sample (24h; top)
Relative Expression (log2-ratio):7.186351Number of Samples:2 / 2
| Experimental | T. cruzi study 1 (HMVEC; 24h; top) |
| Human cardiac microvascular endothelial cells (HMVECs) grown in the transwell top, bathed with media from the HMVECs infected with Trypanosoma cruzi trypomastigotes for 2 hours (10exp8/ml) and harvested 24 hours post infection. In the transwell setup, cells in the top chamber served as reporters for the effect of all difusible factors secreted by parasite-infected cells in the bottom chamber. Cells were maintained in endothelial cell basal medium-2 and endothelial cell growth supplements including 5% FBS. | |
| Control | mock infected cardiac microvascular endothelial cell sample (24h; top) |
| Human cardiac microvascular endothelial cells (HMVECs) grown in the transwell top, bathed with media from the mock-infected bottom HMVECs, harvested 24 hours post mock infection with 2% FBS medium. In the transwell setup, cells in the top chamber served as reporters for the effect of all difusible factors secreted by mock-infected cells in the bottom chamber. Cells were maintained in endothelial cell basal medium-2 and endothelial cell growth supplements including 5% FBS. |
T. cruzi study 1 (BJ; 24h; top) / mock infected foreskin fibroblast (BJ) sample (24h; top)
Relative Expression (log2-ratio):6.6856823Number of Samples:2 / 2
| Experimental | T. cruzi study 1 (BJ; 24h; top) |
| Foreskin fibroblast (BJ) cells grown in the transwell top, bathed with media from the BJ cells infected with Trypanosoma cruzi trypomastigotes for 2 hours (10exp8/ml) and harvested 24 hours post infection. In the transwell setup, cells in the top chamber served as reporters for the effect of all difusible factors secreted by parasite-infected cells in the bottom chamber. Cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin. | |
| Control | mock infected foreskin fibroblast (BJ) sample (24h; top) |
| Foreskin fibroblast (BJ) cells grown in the transwell top, bathed with media from the mock-infected bottom BJ cells, harvested 24 hours post mock infection with 2% FBS medium. In the transwell setup, cells in the top chamber served as reporters for the effect of all difusible factors secreted by mock-infected cells in the bottom chamber. Cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin. |
T. cruzi study 1 (BJ; 24h; bottom) / mock infected foreskin fibroblast (BJ) sample (24h; bottom)
Relative Expression (log2-ratio):6.537938Number of Samples:2 / 2
| Experimental | T. cruzi study 1 (BJ; 24h; bottom) |
| Foreskin fibroblast (BJ) cells grown in the transwell bottom, infected with Trypanosoma cruzi trypomastigotes for 2 hours (10exp8/ml) and harvested 24 hours post infection. Cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin. | |
| Control | mock infected foreskin fibroblast (BJ) sample (24h; bottom) |
| Foreskin fibroblast (BJ) cells grown in the transwell bottom, mock-infected and harvested 24 hours post mock infection with 2% FBS medium. Cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin. |
T. cruzi study 1 (VSMC; 48h) / mock infected vascular smooth muscle cell sample (48h)
Relative Expression (log2-ratio):6.404704Number of Samples:3 / 3
| Experimental | T. cruzi study 1 (VSMC; 48h) |
| Human vascular smooth muscle cells (VSMCs) infected with Trypanosoma cruzi trypomastigotes for 2 hours (10exp8/ml) and harvested 48 hours post infection. Cells were maintained in Ham's F12K medium with 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 10 mM HEPES, 10 mM TES, 0.05 mg/ml ascorbic acid, 0.001 mg/ml insulin, 0.01 mg/ml transferrin, 10ng/ml sodium selenite, 0.03 mg/ml endothelial cell growth supplement (ECGS) and 10% FBS. | |
| Control | mock infected vascular smooth muscle cell sample (48h) |
| Human vascular smooth muscle cells (VSMCs) mock-infected and harvested 48 hours post mock infection with 2% FBS medium. Cells were maintained in Ham's F12K medium with 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 10 mM HEPES, 10 mM TES, 0.05 mg/ml ascorbic acid, 0.001 mg/ml insulin, 0.01 mg/ml transferrin, 10ng/ml sodium selenite, 0.03 mg/ml endothelial cell growth supplement (ECGS) and 10% FBS. |
T. cruzi study 1 (HMVEC; 24h; bottom) / mock infected cardiac microvascular endothelial cell sample (24h; bottom)
Relative Expression (log2-ratio):6.283209Number of Samples:2 / 2
| Experimental | T. cruzi study 1 (HMVEC; 24h; bottom) |
| Human cardiac microvascular endothelial cells (HMVECs) grown in the transwell bottom, infected with Trypanosoma cruzi trypomastigotes for 2 hours (10exp8/ml) and harvested 24 hours post infection. Cells were maintained in endothelial cell basal medium-2 and endothelial cell growth supplements including 5% FBS. | |
| Control | mock infected cardiac microvascular endothelial cell sample (24h; bottom) |
| Human cardiac microvascular endothelial cells (HMVECs) grown in the transwell bottom, mock-infected and harvested 24 hours post mock infection with 2% FBS medium. Cells were maintained in endothelial cell basal medium-2 and endothelial cell growth supplements including 5% FBS. |
LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)
Relative Expression (log2-ratio):6.050024Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA cycT1) |
| MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | cycT1 depletion study 2 (shRNA) |
| MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated. |
glioma study 16 (LN-319) / normal astrocyte sample
Relative Expression (log2-ratio):5.829921Number of Samples:2 / 3
| Experimental | glioma study 16 (LN-319) |
| Human glioma cell line LN319 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):5.779002Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA contr.) |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated / transduced MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
HIF-2a depletion study 1 (normoxia; AB81) / control AB81 cell sample (normoxia)
Relative Expression (log2-ratio):-5.708807Number of Samples:3 / 3
| Experimental | HIF-2a depletion study 1 (normoxia; AB81) |
| Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-2a (Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. | |
| Control | control AB81 cell sample (normoxia) |
| Human podocyte cell line AB81 treated with normoxia (20% O2) for 24 hours. Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. |
dendritic cell study 7 (IL-4 mddc) / dendritic cell study 7 (IL-15 mddc)
Relative Expression (log2-ratio):-5.699213Number of Samples:3 / 3
| Experimental | dendritic cell study 7 (IL-4 mddc) |
| Mature IL-4 dendritic cells differentiated from CD14+ monocytes obtained from healthy donors. Monocytes were seeded in RPMI and supplemented with 2.5 % heat-inactivated human AB serum. Monocytes were cultured with 800 IU/mL granulocyte macrophage colony-stimulating factor and 20 ng/mL IL-4 in order to generate immature IL-4 DCs. Conventional maturation cocktail, comprising 10 ng/mL tumor necrosis factor-α, 10 ng/mL interleukin-1β, 15 ng/ml interleukin-6 and 1 µg/mL prostaglandin E2 was added for 48 hours. CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMC) by Ficoll density gradient centrifugation and purified by positive magnetic cell selection. | |
| Control | dendritic cell study 7 (IL-15 mddc) |
| Mature IL-15 dendritic cells differentiated from CD14+ monocytes obtained from healthy donors. Monocytes were seeded in RPMI and supplemented with 2.5 % heat-inactivated human AB serum. Differentiation was induced with 800 IU/mL granulocyte macrophage colony-stimulating factor and 200 ng/mL IL-15 to obtain immature IL-15 DCs. A TLR-activating maturation cocktail, comprising 3 µg/mL R848, 2.5 ng/mL tumor necrosis factor-α, 250 ng/mL interferon-γ and 1 µg/mL prostaglandin E2 was added after 24-48 hours of differentiation for 18-20 hours. CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMC) by Ficoll density gradient centrifugation and purified by positive magnetic cell selection. |